Down syndrome, a genetic condition caused by the presence of an extra copy of chromosome 21, is the most common genetic cause of intellectual disability. Despite its prevalence, the precise mechanisms by which it disrupts brain advancement during fetal stages have remained largely unknown. Recent research involving the analysis of approximately 250,000 cells from human fetal cortices – specifically, samples from 15 individuals with Down syndrome and 15 control subjects between 10 and 20 weeks post-conception – has begun to illuminate these processes.
The study, utilizing single-cell transcriptomic and chromatin accessibility profiling, identified a specific decrease in a subtype of excitatory neurons expressing the proteins RORB and FOXP1. Researchers also observed widespread disruptions in the genetic programs governing neurodevelopment. Further analysis pinpointed three transcription factors located on chromosome 21 - BACH1, PKNOX1, and GABPA – as key regulators. These factors appear to be particularly sensitive to dosage imbalances and influence genes strongly associated with intellectual disability.
In vitro experiments demonstrated that restoring normal levels of these transcription factors using antisense oligonucleotides partially reversed the abnormal gene expression patterns. Complementary findings were obtained from a humanized in vivo model, which revealed additional molecular and cellular characteristics of Down syndrome.The research team has made their data publicly available, creating a valuable resource for future investigations into the genetic and regulatory landscape of cortical development in Down syndrome, and identifying potential therapeutic targets.
